131 related articles for article (PubMed ID: 37555475)
1. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells.
Twum Y; Marshall K; Gao W
Biofactors; 2023; 49(6):1143-1157. PubMed ID: 37555475
[TBL] [Abstract][Full Text] [Related]
2. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
3. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
4. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
Oh HN; Kwak AW; Lee MH; Kim E; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
[TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
[TBL] [Abstract][Full Text] [Related]
8. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
9. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
Peng C; Li P; Yang M; Chen D; Huang Y
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):538-547. PubMed ID: 34334155
[TBL] [Abstract][Full Text] [Related]
10. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA
J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873
[TBL] [Abstract][Full Text] [Related]
11. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
12. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
13. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
14. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
15. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
16. Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells.
Cui J; Zhao S; Chen H; Fu Y; Han K; Yin S; Zhao C; Fan L; Hu H
Biochem Pharmacol; 2023 Sep; 215():115690. PubMed ID: 37481142
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
20.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]